FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W269061822> ?p ?o ?g. }

• W269061822 endingPage "352" @default.
• W269061822 startingPage "347" @default.
• W269061822 abstract "The usefulness of Holter monitoring (HM) in selecting pharmacologic therapy for patients with sustained monomorphic ventricular tachycardia (VT) was evaluated in patients in whom no effective pharmacologic therapy could be determined in an electrophysiologic study (EPS). The study population consisted of 49 consecutive patients with sustained VT who were receiving long-term pharmacologic therapy despite the fact that no pharmacologic therapy had been found to be effective in the EPS. The efficacy of the pharmacologic therapies was assessed by HM. A reduction in frequent (10/h) premature ventricular contractions (PVCs) was used as an index of treatment efficacy, with therapies achieving substantial PVC suppression (>70% of all PVCs) being considered to be effective (HM effective group). When no therapy was found to be effective when assessed by HM, a drug with any other beneficial effect, eg, reduction in VT rate, was chosen (HM ineffective group). VT recurrence and survival were compared between groups. During the follow-up period of 31±28 months, VT recurrence was observed in a total of 25/49 patients: 3/17 patients in the HM effective group, in 18/25 in the HM ineffective group, and in 4/7 in the HM undetermined group (p=0.0487). Sudden cardiac death occurred in a total 7/49 patients: 2/17 patients in the HM effective group, 4/25 patients in the HM ineffective group, and 1/7 patient in the HM undetermined group (p=0.2828). Among patients in whom no effective therapy could be determined by EPS, the VT recurrence rate was significantly lower in the group in whom treatment was effective as assessed by HM than among those in whom treatment was assessed by HM to be ineffective. Sudden cardiac death rate was also lowest in the HM effective group, although the difference was not statistically significant. HM assessment was considered useful in selection of pharmacologic therapy for patients in whom no effective therapy could be determined in the EPS. (Jpn Circ J 1998; 62: 347 - 352)" @default.
• W269061822 created "2016-06-24" @default.
• W269061822 creator A5003308408 @default.
• W269061822 creator A5019980109 @default.
• W269061822 creator A5052401062 @default.
• W269061822 creator A5055227838 @default.
• W269061822 creator A5060689933 @default.
• W269061822 creator A5076393967 @default.
• W269061822 date "1998-01-01" @default.
• W269061822 modified "2023-09-25" @default.
• W269061822 title "The Usefulness of Holter Monitoring in Selecting Pharmacologic Therapy for Patients With Sustained Monomorphic Ventricular Tachycardia" @default.
• W269061822 cites W1967900132 @default.
• W269061822 cites W2003773211 @default.
• W269061822 cites W2017735065 @default.
• W269061822 cites W2020360859 @default.
• W269061822 cites W2035541940 @default.
• W269061822 cites W2037812290 @default.
• W269061822 cites W2040019984 @default.
• W269061822 cites W2045686600 @default.
• W269061822 cites W2051989575 @default.
• W269061822 cites W2052675296 @default.
• W269061822 cites W2071402151 @default.
• W269061822 cites W2100069431 @default.
• W269061822 cites W2128075347 @default.
• W269061822 cites W2161963243 @default.
• W269061822 cites W2170576011 @default.
• W269061822 cites W2331274093 @default.
• W269061822 cites W2335437178 @default.
• W269061822 cites W2337679965 @default.
• W269061822 cites W2516261599 @default.
• W269061822 cites W2561285689 @default.
• W269061822 doi "https://doi.org/10.1253/jcj.62.347" @default.
• W269061822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9626902" @default.
• W269061822 hasPublicationYear "1998" @default.
• W269061822 type Work @default.
• W269061822 sameAs 269061822 @default.
• W269061822 citedByCount "10" @default.
• W269061822 countsByYear W2690618222021 @default.
• W269061822 crossrefType "journal-article" @default.
• W269061822 hasAuthorship W269061822A5003308408 @default.
• W269061822 hasAuthorship W269061822A5019980109 @default.
• W269061822 hasAuthorship W269061822A5052401062 @default.
• W269061822 hasAuthorship W269061822A5055227838 @default.
• W269061822 hasAuthorship W269061822A5060689933 @default.
• W269061822 hasAuthorship W269061822A5076393967 @default.
• W269061822 hasBestOaLocation W2690618221 @default.
• W269061822 hasConcept C126322002 @default.
• W269061822 hasConcept C164705383 @default.
• W269061822 hasConcept C2776331378 @default.
• W269061822 hasConcept C42219234 @default.
• W269061822 hasConcept C71924100 @default.
• W269061822 hasConceptScore W269061822C126322002 @default.
• W269061822 hasConceptScore W269061822C164705383 @default.
• W269061822 hasConceptScore W269061822C2776331378 @default.
• W269061822 hasConceptScore W269061822C42219234 @default.
• W269061822 hasConceptScore W269061822C71924100 @default.
• W269061822 hasIssue "5" @default.
• W269061822 hasLocation W2690618221 @default.
• W269061822 hasLocation W2690618222 @default.
• W269061822 hasOpenAccess W269061822 @default.
• W269061822 hasPrimaryLocation W2690618221 @default.
• W269061822 hasRelatedWork W1534090624 @default.
• W269061822 hasRelatedWork W1604781429 @default.
• W269061822 hasRelatedWork W1975096445 @default.
• W269061822 hasRelatedWork W1991344869 @default.
• W269061822 hasRelatedWork W2030004221 @default.
• W269061822 hasRelatedWork W2069600595 @default.
• W269061822 hasRelatedWork W2081920711 @default.
• W269061822 hasRelatedWork W2090518947 @default.
• W269061822 hasRelatedWork W301972232 @default.
• W269061822 hasRelatedWork W4206484244 @default.
• W269061822 hasVolume "62" @default.
• W269061822 isParatext "false" @default.
• W269061822 isRetracted "false" @default.
• W269061822 magId "269061822" @default.
• W269061822 workType "article" @default.